Curanex Pharmaceuticals Inc Common Stock Total Liabilities
Curanex Pharmaceuticals Inc Common Stock total liabilities. Based on the latest financial reports, Curanex Pharmaceuticals Inc Common Stock (CURX) has total liabilities worth $185.96K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Curanex Pharmaceuticals Inc Common Stock (CURX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Curanex Pharmaceuticals Inc Common Stock (2022–2024)
Total liabilities of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024. This chart illustrates how Curanex Pharmaceuticals Inc Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Curanex Pharmaceuticals Inc Common Stock Competitors by Total Liabilities
The table below lists competitors of Curanex Pharmaceuticals Inc Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nimy Resources Ltd
AU:NIM
|
Australia | AU$4.88 Million |
|
Focus Dynamics Group Bhd
KLSE:0116
|
Malaysia | RM228.62 Million |
|
Green Technology Metals Ltd
AU:GT1
|
Australia | AU$7.41 Million |
|
A.G.Barr PLC
LSE:BAG
|
UK | GBX168.60 Million |
|
Mandrake Resources Ltd
AU:MAN
|
Australia | AU$57.41K |
|
Corus Entertainment Inc
TO:CJR-B
|
Canada | CA$2.04 Billion |
|
Natural Health Trends Corp
F:NAH
|
Germany | €15.49 Million |
|
Quhuo Limited American Depository Shares
NASDAQ:QH
|
USA | $448.76 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down Curanex Pharmaceuticals Inc Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Curanex Pharmaceuticals Inc Common Stock.
Liquidity & Leverage Metrics
Curanex Pharmaceuticals Inc Common Stock Total Liabilities Ratios Explained
Curanex Pharmaceuticals Inc Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 77.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Curanex Pharmaceuticals Inc Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Curanex Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual total liabilities of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.57K | +2.09% |
| 2023-12-31 | $14.28K | -- |
| 2022-12-31 | $0.00 | -- |
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma… Read more